Judge Dismisses Soliris Antitrust Suit Against Alexion

A federal judge in Massachusetts tossed a proposed class action accusing Alexion Pharmaceuticals of patent misuse to block cheaper rivals to Soliris.

Updated on Nov. 16, 2026 in Healthcare

Judge Dismisses Soliris Antitrust Suit Against Alexion

US District Judge Brian Murphy dismissed a proposed class-action lawsuit against Alexion Pharmaceuticals, a subsidiary of AstraZeneca, over the rare-disease drug Soliris. The suit, brought by health plan EmblemHealth on behalf of US Soliris purchasers, alleged Alexion misused patents to maintain a monopoly.

Why it matters

The ruling leaves in place Alexion's protection from antitrust liability for enforcing intellectual property rights, a defense that can shape how drug makers respond to competition from biosimilars. EmblemHealth said it is reviewing the decision and will determine next steps.

AstraZeneca reported more than $1.8 billion in Soliris revenue last year, while EmblemHealth alleges overpayments above $2 billion tied to delayed biosimilar competition. The judge's ruling did not evaluate those figures, and the overpayment estimate remains an allegation.

The players

Alexion Pharmaceuticals

Alexion is a biopharmaceutical company and subsidiary of AstraZeneca that markets Soliris, a treatment for rare blood disorders.

AstraZeneca

AstraZeneca is a multinational pharmaceutical company headquartered in Cambridge, England, and the parent of Alexion.

EmblemHealth

EmblemHealth is a New York-based health insurance company that brought the class action on behalf of US Soliris purchasers.

The details

Judge Brian Murphy rejected EmblemHealth's argument that Alexion brought allegedly sham litigation to enforce its patents, finding the company immune under a doctrine that generally shields intellectual property enforcement from antitrust claims. EmblemHealth alleged Alexion obtained new patents after the originals expired to block biosimilar versions of Soliris for four years, and misled the US Patent and Trademark Office to secure them.

Timeline

  1. Last year: AstraZeneca earned more than $1.8 billion from Soliris sales.

  2. Four years after original patents expired: period EmblemHealth alleges Alexion blocked biosimilars.

  3. March 2025: earliest date EmblemHealth alleges biosimilars could be delayed until.

  4. November 16, 2026: Judge Murphy dismissed the proposed class action.

Industry Landscape

The ruling applies the Noerr-Pennington doctrine, which generally protects patent enforcement from antitrust liability, to a challenge over Soliris biosimilar delays. It illustrates how that defense can shape pricing competition in specialty drug markets.

Patients relying on Soliris for rare blood disorders see no immediate change in access or cost from this ruling. Purchasers who brought the suit lose this avenue for recovery, and any future biosimilar entry will depend on separate regulatory and market developments.

The takeaway

Patent-based defenses can be powerful shields in pharmaceutical antitrust litigation, so the practical effect of rulings like this often depends on whether biosimilar competition arrives on schedule. Readers tracking drug costs should watch for any appeal or new filing by EmblemHealth.

Further reading

For related coverage of drug pricing and competition, see Healthcare in the Massachusetts section.